ANNX
Annexon, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.01
+17.60%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -3.7%
- EBIT
- -4.7%
- EPS
- +10.1%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- -8.4%
- EPS
- +6.0%
Three-year CAGR
- Revenue
- —
- EBITDA
- -50.3%
- EBIT
- -40.5%
- Net income
- -49.6%
- EPS
- -32.7%
- Free cash flow
- -58.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026